MOTS-C vs SLU-PP-332: Mechanism, Half-Life & Research Use
MOTS-c and SLU-PP-332 are prominent investigational compounds studied for their distinct roles in mitochondrial biogenesis, exercise capacity, and metabolic regulation. While MOTS-c functions as a mitochondrial-derived peptide that translocates to the nucleus to regulate folate-purine biosynthesis and activate AMPK, SLU-PP-332 is a synthetic pan-agonist of estrogen-related receptors (ERRs) that directly alters transcription of oxidative oxidative metabolic genes.
Quick answer
MOTS-c and SLU-PP-332 are prominent investigational compounds studied for their distinct roles in mitochondrial biogenesis, exercise capacity, and metabolic regulation. While MOTS-c functions as a mitochondrial-derived peptide that translocates to the nucleus to regulate folate-purine biosynthesis and activate AMPK, SLU-PP-332 is a synthetic pan-agonist of estrogen-related receptors (ERRs) that directly alters transcription of oxidative oxidative metabolic genes.
Key takeaways
- In modern bio-energetic literature, researchers frequently compare mitochondrial-derived signaling molecules with synthetic transcriptional modulators.
- To select the appropriate reagent for downstream bio-assays, lab personnel must evaluate fundamental biochemical parameters.
- Preclinical studies show that [MOTS-c](/research-peptides/mots-c) acts primarily via a unique metabolic sensing network.
- SLU-PP-332 operates via a distinct nuclear receptor framework by binding to ERRα, ERRβ, and ERRγ.
Comparative Structural Profiles: MDP vs. Pan-ERR Agonist
In modern bio-energetic literature, researchers frequently compare mitochondrial-derived signaling molecules with synthetic transcriptional modulators. MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a naturally occurring 16-amino-acid peptide encoded within the mitochondrial genome. It represents an endogenous endocrine-like peptide signal that coordinates intracellular communication between the mitochondria and the cell nucleus during metabolic stress. Investigations utilizing our mots-c vs slu-pp-332 research catalog emphasize its capacity to modulate systemic homeostasis via AMPK activation.
Conversely, SLU-PP-332 is a synthetic small-molecule agonist developed to target the estrogen-related receptor (ERR) family, specifically ERRα, ERRβ, and ERRγ. Unlike mitochondrial peptides that interact with complex enzymatic Cascades, SLU-PP-332 functions directly as a nuclear receptor ligand. It mimics physical exercise programs at the molecular level by upregulating genetic networks involved in fatty acid oxidation, mitochondrial electron transport chain synthesis, and slow-twitch muscle fiber conversion.
Preclinical Specifications: MOTS-C vs SLU-PP-332
To select the appropriate reagent for downstream bio-assays, lab personnel must evaluate fundamental biochemical parameters. The table below delineates the key analytical properties of MOTS-c lyophilized powder and SLU-PP-332 across primary experimental dimensions.
| Criteria | MOTS-c (Mitochondrial Peptide) | SLU-PP-332 (Pan-ERR Agonist) | | :--- | :--- | :--- | | **Receptor / Target** | AMPK / Folate-Purine Biosynthesis / AICAR pathway | Estrogen-Related Receptors (ERRα, ERRβ, ERRγ) | | **Mechanistic Class** | Mitochondrial-Derived Peptide (MDP) | Synthetic Pan-ERR Nuclear Receptor Agonist | | **Reported Plasma Half-Life** | Short (~ several minutes in plasma; extended nuclear action) | Moderate (~30–90 minutes in rodent pharmacokinetic models) | | **Primary Solubility** | Aqueous buffers (PBS, Sterile Water) | Organic Solvents (DMSO, Ethanol) / Co-solvent mixtures | | **Preclinical Assay Models** | Rodent diet-induced obesity, metabolic stress, insulin sensitivity | Rodent endurance performance, muscular dystrophy, oxidative fiber switch | | **Standard Research Configurations** | 5 mg, 10 mg lyophilized vials | Standard laboratory research grade powders / solutions | | **Primary Biomarkers Monitored** | p-AMPK, GLUT4, AICAR accumulation, C/EBPβ | ERRα target genes, PGC-1α, PGC-1β, Citrate Synthase activity |
MOTS-C Mechanism of Action: AMPK and Nuclear Translocation
Preclinical studies show that MOTS-c acts primarily via a unique metabolic sensing network. Upon cellular stress, such as glucose deprivation or metabolic burden, MOTS-c translocates from the cytoplasm to the nucleus. Inside the nucleus, it binds directly to specific transcription factors, including baseline elements involved in the folate-purine biosynthesis axis. This inhibition of the folate cycle leads to an accumulation of the endogenous AMPK activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR).
Through downstream AMPK activation, MOTS-c has been observed in animal models to promote glucose uptake independently of classic insulin signaling pathways. Research models demonstrate that administration of high-purity MOTS-c enhances skeletal muscle glucose clearance, reduces hepatic steatosis, and restores metabolic plasticity in diet-induced obese mice. Laboratories evaluating this pathway rely on validated analytical standards confirmed by a lot-specific certificate of analysis to maintain consistent baseline data.
SLU-PP-332 Mechanism of Action: Direct Pan-ERR Activation
SLU-PP-332 operates via a distinct nuclear receptor framework by binding to ERRα, ERRβ, and ERRγ. Estrogen-related receptors are orphan nuclear receptors that control the transcription of mitochondrial genes governing oxidative phosphorylation, fatty acid β-oxidation, and mitochondrial biogenesis. By activating ERRα in tandem with its co-activator PGC-1α, SLU-PP-332 induces an exercise-mimetic transcriptional program in skeletal muscle and cardiac tissue.
In vivo rodent models treated with SLU-PP-332 demonstrate marked increases in energy expenditure, elevated mitochondrial mass within type I (slow-twitch) oxidative muscle fibers, and enhanced fatigue resistance during treadmill performance assays. Unlike peptide signals that depend on intermediate enzymatic steps, SLU-PP-332 directly recruits nuclear co-activators to upregulate enzymes such as carnitine palmitoyltransferase 1A (CPT1A) and pyruvate dehydrogenase kinase 4 (PDK4).
Pharmacokinetics, Half-Life, and Tissue Distribution
Understanding the pharmacokinetics of both compounds is essential for designing accurate dosing schedules in preclinical animal research. In plasma, peptide compounds like MOTS-c undergo rapid enzymatic degradation by endogenous peptidases. Rodent pharmacokinetic studies report a plasma elimination half-life of only several minutes following parenteral administration. However, the downstream cellular effects—such as nuclear translocation, transcriptional reprogramming, and sustained AMPK phosphorylation—persist for several hours past circulating clearance.
SLU-PP-332, as a non-peptidic synthetic small molecule, exhibits a longer plasma half-life relative to un-modified peptides, typically falling within the range of 30 to 90 minutes in rodent pharmacokinetic assays depending on vehicle formulation. However, due to its high lipophilicity, SLU-PP-332 requires specialized solvent systems (e.g., DMSO, PEG-400, or cyclodextrin carriers) to ensure uniform bioavailability in animal models, whereas MOTS-c readily dissolves in physiological aqueous media.
Comparative Analysis: Energy Expenditure and Metabolic Class Pathways
When designing comparative research protocols in metabolic regulation, researchers often analyze multiple metabolic compounds within the same experimental framework. For instance, studies investigating energy expenditure may evaluate MOTS-c alongside SLU-PP-332, Humanin, and 5-Amino-1MQ to isolate distinct enzymatic pathways. While MOTS-c and Humanin belong to the mitochondrial-derived peptide family that alters stress response pathways, 5-Amino-1MQ inhibits nicotinamide N-methyltransferase (NNMT) to preserve NAD+ pools, and SLU-PP-332 acts as a direct nuclear transcriptional agonist.
Preclinical data indicate that while MOTS-c excels in models of acute metabolic stress and insulin resistance via AMPK signaling, SLU-PP-332 exhibits superior capacity for remodeling structural muscle architecture toward an oxidative phenotype. Combining or comparing these agents in vitro allows laboratories to dissect the exact contributions of mitochondrial-nuclear cross-talk versus direct ERR nuclear receptor stimulation.
Selecting MOTS-C vs. SLU-PP-332 for Specific Study Designs
Choosing between MOTS-c and SLU-PP-332 depends primarily on the targeted endpoints of the experimental model. Laboratories focused on systemic insulin sensitivity, glucose transporter 4 (GLUT4) translocation, and mitochondrial-nuclear stress signaling generally select MOTS-c. Its endogenous peptide structure makes it an ideal candidate for exploring mitochondrial signal transduction and folate cycle interactions in cell culture and preclinical rodent assays.
Conversely, researchers prioritizing physical performance, oxygen consumption ($VO_2$ max), lipid oxidation rates, or muscle fiber type transformation often deploy SLU-PP-332. Its potent pan-ERR agonist activity provides a robust model for investigating pharmacologic exercise mimetic responses without requiring cellular stress-induced activation cascades. For precise stock concentration math across diverse assay plates, researchers utilize our lab reconstitution calculator tool.
Reconstitution, Handling, and In Vitro Preparation
Proper reconstitutions and vehicle selections are critical to ensure reproducibility in laboratory settings. MOTS-c is supplied as a lyophilized peptide powder. It should be reconstituted using sterile bacteriostatic water or phosphate-buffered saline (PBS, pH 7.4). After reconstitution, aliquots should be stored at -20°C or -80°C to minimize freeze-thaw degradation cycles. Avoid prolonged exposure to room temperature to preserve peptide bond integrity.
SLU-PP-332 requires different handling due to its hydrophobic nature. Stock solutions are typically prepared using high-purity dimethyl sulfoxide (DMSO) or ethanol before dilution into working culture media or physiological injection vehicles. Research protocols must include vehicle control groups (e.g., matching DMSO percentages) when comparing SLU-PP-332 to aqueous MOTS-c treatments to account for solvent-induced cellular responses.
Quality Assurance: Verification of Research Grade Reagents
Experimental integrity in preclinical research depends on high reagent purity and rigorous analytical verification. At PX1 Research, all research compounds—including mitochondrial peptides and synthetic nuclear agonists—undergo mandatory testing at certified ISO 17025 laboratories in the USA. Purity is validated using High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) to guarantee identity, exact molecular mass, and freedom from synthesis side-products.
Additionally, end-product testing includes chromogenic limulus amebocyte lysate (LAL) assays for endotoxin verification. Maintaining endotoxin levels below established research thresholds prevents non-specific inflammatory responses in cell cultures and animal models. Investigational facilities sourcing from our bulk lab supply portal receive lot-specific documentation verifying batch uniformity, purity (>99%), and stability.
Frequently Asked Questions
What is the primary difference in mechanism between MOTS-c and SLU-PP-332?
MOTS-c is a mitochondrial-derived peptide that translocates to the nucleus to modulate folate-purine synthesis and activate AMPK. SLU-PP-332 is a synthetic small-molecule pan-agonist that directly activates estrogen-related receptors (ERRα/β/γ) to induce oxidative gene transcription.
How do the reported half-lives of MOTS-c and SLU-PP-332 compare in preclinical models?
MOTS-c exhibits a short plasma half-life of several minutes in rodents, though its nuclear transcriptional downstream signaling persists for hours. SLU-PP-332 has a longer plasma elimination half-life (~30–90 minutes in rodent models) but requires organic solvent vehicles due to lipophilicity.
What reconstituted vehicles are recommended for in vitro assays?
MOTS-c readily dissolves in aqueous buffers such as sterile water or PBS. SLU-PP-332 requires organic solvents like DMSO or specialized co-solvent formulations for complete dissolution prior to media addition.
Are MOTS-c and SLU-PP-332 intended for human or veterinary administration?
No. Both compounds are strictly designated for in vitro and preclinical laboratory research use only. They are not for human or animal therapeutic, diagnostic, or clinical applications.
How is the purity of MOTS-c validated by PX1 Research?
Every lot of MOTS-c undergoes HPLC and Mass Spectrometry (MS) analysis at an independent ISO 17025 accredited laboratory in the USA to confirm purity ≥99% and verified mass, accompanied by an endotoxin screening certificate.
Which compound is better suited for studying skeletal muscle fiber transformation?
Preclinical literature indicates SLU-PP-332 is specifically suited for studying muscle fiber transformation toward type I oxidative fibers due to direct ERRα/PGC-1α gene activation. MOTS-c is more commonly selected for systemic glucose metabolism and AMPK signaling assays.
Where can detailed assay protocols and technical research papers be reviewed?
Researchers can access comprehensive analytical data, literature citations, and compound specifications directly on the official [PX1 research hub](/research).
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.